Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, September 9, 2025, at 3:20 PM ET at the Sheraton New York Times Square and engage in one-on-one investor meetings.
Investors can access a live audio webcast of the presentation through Erasca.com/events, with a replay available for 30 days following the event.
Erasca (Nasdaq: ERAS), società clinica focalizzata su terapie oncologiche mirate contro i tumori guidati dalla via RAS/MAPK, parteciperà alla Morgan Stanley 23rd Annual Global Healthcare Conference. Il management terrà una presentazione il martedì 9 settembre 2025 alle 15:20 ET presso lo Sheraton New York Times Square e svolgerà incontri individuali con investitori.
Gli investitori potranno seguire la presentazione in diretta audio tramite Erasca.com/events; la registrazione sarà disponibile in replay per 30 giorni dopo l'evento.
Erasca (Nasdaq: ERAS), una compañía en fase clínica centrada en terapias oncológicas de precisión dirigidas a tumores impulsados por la vía RAS/MAPK, participará en la Morgan Stanley 23rd Annual Global Healthcare Conference. La dirección ofrecerá una presentación el martes 9 de septiembre de 2025 a las 3:20 PM ET en el Sheraton New York Times Square y mantendrá reuniones individuales con inversores.
Los inversores podrán escuchar la transmisión de audio en directo en Erasca.com/events; la repetición estará disponible durante 30 días tras el evento.
Erasca (Nasdaq: ERAS), RAS/MAPK 경로 중심의 정밀 종양학 치료제를 개발하는 임상 단계 기업이 Morgan Stanley 23rd Annual Global Healthcare Conference에 참가합니다. 경영진은 2025년 9월 9일 화요일 동부시간 오후 3시 20분에 Sheraton New York Times Square에서 발표를 진행하고 1:1 투자자 미팅을 가질 예정입니다.
투자자는 Erasca.com/events에서 발표의 오디오 생중계를 들을 수 있으며, 행사가 끝난 후 30일 동안 재청취가 가능합니다.
Erasca (Nasdaq: ERAS), entreprise en phase clinique spécialisée dans des thérapies oncologiques de précision ciblant les cancers pilotés par la voie RAS/MAPK, participera à la Morgan Stanley 23rd Annual Global Healthcare Conference. La direction présentera le mardi 9 septembre 2025 à 15h20 ET au Sheraton New York Times Square et mènera des réunions individuelles avec des investisseurs.
Les investisseurs pourront suivre la retransmission audio en direct via Erasca.com/events ; un replay sera disponible pendant 30 jours après l'événement.
Erasca (Nasdaq: ERAS), ein klinisch fortgeschrittenes Unternehmen für präzisionsonkologische Therapien, die durch den RAS/MAPK-Signalweg gesteuerte Tumoren adressieren, wird an der Morgan Stanley 23rd Annual Global Healthcare Conference teilnehmen. Das Management wird am Dienstag, 9. September 2025, um 15:20 Uhr ET im Sheraton New York Times Square eine Präsentation halten und Einzelgespräche mit Investoren führen.
Investoren können die Präsentation als Live-Audio-Webcast über Erasca.com/events verfolgen; ein Replay ist 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference being held at the Sheraton New York Times Square in New York, NY. Management will present on Tuesday, September 9, 2025, at 3:20 pm Eastern Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
When is Erasca (ERAS) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Erasca's Morgan Stanley conference presentation?
What type of company is Erasca (ERAS)?
Where will the Morgan Stanley Healthcare Conference 2025 be held?
